{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vascular:pad:cilostazol",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-07T01:30:00.000Z",
    "updated": "2026-01-07T01:30:00.000Z",
    "contributors": [
      "vascular-surgery-agent"
    ],
    "confidence": 0.93,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "medium"
  },
  "content": {
    "identifier": "PAD-016",
    "title": "Cilostazol for Intermittent Claudication",
    "definition": "A phosphodiesterase-3 inhibitor with vasodilatory and antiplatelet properties, FDA-approved for treatment of intermittent claudication to improve walking distance.",
    "concepts": [
      {
        "concept_id": "mechanism",
        "term": "Mechanism of Action",
        "definition": "How cilostazol works.",
        "clinical_features": {
          "pde3_inhibition": "Inhibits phosphodiesterase-3 in platelets and vascular smooth muscle",
          "camp": "Increases cyclic AMP leading to vasodilation",
          "antiplatelet": "Inhibits platelet aggregation"
        }
      },
      {
        "concept_id": "efficacy",
        "term": "Clinical Efficacy",
        "definition": "Evidence for cilostazol in claudication.",
        "clinical_features": {
          "walking_distance": "Increases maximal walking distance by 40-60%",
          "onset": "Improvement typically seen by 4-12 weeks",
          "comparison": "Superior to pentoxifylline in clinical trials"
        }
      },
      {
        "concept_id": "contraindications",
        "term": "Contraindications",
        "definition": "When to avoid cilostazol.",
        "clinical_features": {
          "heart_failure": "Contraindicated in heart failure (any severity)",
          "bleeding": "Caution with other antiplatelet/anticoagulant agents",
          "headache": "Most common side effect (30-40%), often resolves"
        }
      }
    ],
    "clinical_features": {
      "guideline_recommendation": "First-line pharmacotherapy for claudication (AHA/ACC)",
      "role": "Adjunct to exercise therapy, not replacement"
    },
    "statement": "Cilostazol for Intermittent Claudication is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Cilostazol for Intermittent Claudication helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Cilostazol for Intermittent Claudication include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Cilostazol for Intermittent Claudication."
    }
  },
  "relationships": [
    {
      "type": "treats",
      "target": "vascular:condition:intermittent-claudication"
    },
    {
      "type": "adjunct_to",
      "target": "vascular:treatment:supervised-exercise"
    }
  ],
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). Cilostazol for Intermittent Claudication. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "internal medicine residents",
      "cardiology fellows"
    ],
    "estimated_time": "10min",
    "learning_objectives": [
      "Understand mechanism of action of cilostazol",
      "Apply guideline recommendations for claudication pharmacotherapy",
      "Recognize contraindications and side effects"
    ],
    "clinical_pearls": [
      "BLACK BOX WARNING: Contraindicated in heart failure of ANY severity",
      "First-line pharmacotherapy per AHA/ACC 2017 guidelines",
      "Increases walking distance 40-60% - better than pentoxifylline",
      "Headache is most common side effect (30-40%) but often resolves",
      "Adjunct to supervised exercise, not replacement",
      "Trial for 4-12 weeks before assessing response"
    ],
    "board_yield": "MEDIUM"
  },
  "medicalCode": [
    {
      "codingSystem": "RxNorm",
      "codeValue": "203160",
      "description": "Cilostazol 100 MG Oral Tablet"
    }
  ]
}